NOBIVAC® Canine 1-Pv | Merck Animal Health USA

Canine 1-Pv

A proven method for protecting dogs against all strains of canine parvovirus.

Canine Parvovirus (modified live virus).

Protects against all known CPV strains, including CPV-2c^2,3
- Contains CPV-2b, one of the most prevalent field strains of parvovirus
First to publish data showing protection against CPV-2c challenge²
Study showed no clinical signs of infection in vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains²
High antigenic mass (titer), low passage vaccine protects against all field strains currently seen
Multiple studies demonstrate the ability to override maternal antibodies¹

Shown to be effective for vaccination of healthy dogs 6 weeks of age or older against canine parvovirus.

Nobivac^® vaccines have been demonstrated in multiple studies to override maternal antibodies.¹

Demonstrated to induce 100% seroconversion to CPV after the first round of vaccination at 6 weeks of age¹

Maternal antibodies can interfere with vaccination

Interfering maternally derived antibodies are a primary cause of vaccine failure⁹
Puppies may be susceptible if the level of antibodies to CPV is sufficient to cause failure but insufficient to provide protection⁹
A vaccine that does not override maternal antibodies can make vaccination scheduling difficult⁹

Subcutaneous or intramuscular injection
Two 1 mL doses given 2 to 4 weeks apart
Repeat dose 2 to 4 weeks later. Two doses are required for primary immunization.
Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.
Available in a 25 x 1 mL dose presentation